Benoxaprofen
(Synonyms: 氧苯恶唑丙酸,LRCL 3794) 目录号 : GC49836
An NSAID
Cas No.:51234-28-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Benoxaprofen is a non-steroidal anti-inflammatory drug.1 It inhibits prostaglandin E2 and leukotriene C4 production in isolated mouse peritoneal macrophages stimulated with A23187 when used at a concentration of 100 µM.2 Benoxaprofen (25 and 50 µg/ml) inhibits serum-induced chemotaxis of isolated rat peritoneal leukocytes.3 It induces hemolysis in isolated human erythrocytes and histamine release in isolated rat peritoneal mast cells in a light-dependent manner when used at a concentration of 10 µM.4 Benoxaprofen reduces carrageenan-induced paw edema and yeast-induced fever in rats and acetic acid-induced writhing in mice in a dose-dependent manner.1 Formulations containing benoxaprofen have previously been used in the treatment of osteoarthritis and rheumatoid arthritis.
1.Cashin, C.H., Dawson, W., and Kitchen, E.A.The pharmacology of benoxaprofen (2-[4-chlorophenyl]-α-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesisJ. Pharm. Pharmacol.29(6)330-336(1977) 2.Brune, K., Aehringhaus, U., and Peskar, B.A.Pharmacological control of leukotriene and prostaglandin production from mouse peritoneal macrophagesAgents Actions14(5-6)729-734(1984) 3.Meacock, S.C., and Kitchen, E.A.Effects of the non-steroidal anti-inflammatory drug benoxaprofen on leucocyte migrationJ. Pharm. Pharmacol.31(6)366-370(1979) 4.Sik, R.H., Paschall, C.S., and Chignell, C.F.The phototoxic effect of benoxaprofen and its analogs on human erythrocytes and rat peritoneal mast cellsPhotochem. Photobiol.38(4)411-415(1983)
| Cas No. | 51234-28-7 | SDF | Download SDF |
| 别名 | 氧苯恶唑丙酸,LRCL 3794 | ||
| Canonical SMILES | O=C(C(C)C1=CC=C2OC(C3=CC=C(Cl)C=C3)=NC2=C1)O | ||
| 分子式 | C16H12ClNO3 | 分子量 | 301.7 |
| 溶解度 | N/A | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3146 mL | 16.5728 mL | 33.1455 mL |
| 5 mM | 0.6629 mL | 3.3146 mL | 6.6291 mL |
| 10 mM | 0.3315 mL | 1.6573 mL | 3.3146 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Benoxaprofen-induced photo-onycholysis
J Am Acad Dermatol 1982 Nov;7(5):678-80.PMID:7142476DOI:10.1016/s0190-9622(82)70151-3.
Benoxaprofen (Opren) is a nonsteroidal anti-inflammatory agent used in the treatment of arthritis. Photosensitivity, including onycholysis, has been reported in the rheumatologic literature. This drug has recently been approved for use in the United States under the name of Oraflex. In order to alert the dermatology community, we report a case of photo-onycholysis which developed in a patient being treated with Benoxaprofen and review the data on this drug and its side effects.
Phototoxicity to Benoxaprofen
Eur J Rheumatol Inflamm 1982;5(2):124-37.PMID:7084276doi
Photosensitization to Benoxaprofen has been studied in human volunteers. The wavelengths that mediate the reaction lie mainly just outside the sunburn range in the near ultraviolet, UVA region including, however the terminal portion of the UVB region. The photosensitivity reaction begins with sharp burning during exposure, sometimes accompanied by itching. This may be followed by erythema and a flare, which generally fade in about one hour or less. High doses of ultraviolet light can elicit whealing. Photosensitivity to Benoxaprofen is typically an immediate-type, short-lived reaction, dominated by subjective sensations of burning-smarting and redness. With large UVA doses, a sunburn-type reaction may also be present at 24 hours. The photosensitivity is of the phototoxic type. It may appear within 48 hours of starting the drug and usually disappears with 48 hours after stopping. The population most at risk are type 1 and type 2 light-skinned persons who burn easily and tan poorly. Pigmented races are quite resistant, viz, blacks and orientals. Dark-skinned type 4 Caucasoids, such as Mexicans, Indians, etc., have high innate protection. Deep tanning and SPF 15 sunscreens provide adequate protection.
Benoxaprofen improves psoriasis. A double-blind study
Arch Dermatol 1983 Jul;119(7):548-52.PMID:6407402doi
The pathophysiologic significance of increased levels of lipoxygenase compounds in psoriatic lesions was assessed in a double-blind randomized clinical study with the 5-lipoxygenase inhibitor, Benoxaprofen. Forty patients with psoriasis vulgaris were treated with 600 mg of oral Benoxaprofen daily or a placebo for a period of eight weeks. Benoxaprofen therapy provided excellent treatment results in about 75% of the cases. In the placebo group, only minimal improvement occurred. Most patients receiving Benoxaprofen therapy reported side effects including photosensitivity, onycholysis, milia, diarrhea, and edema. In two cases, Benoxaprofen was withdrawn before completion of the treatment course because of photosensitivity. Benoxaprofen may affect psoriatic epidermis either directly by the inhibition of epidermal 5-lipoxygenase or indirectly by the inhibition of the accumulation of phagocytes in psoriatic lesions. Despite serious side effects from Benoxaprofen therapy, lipoxygenase-inhibiting agents deserve further study in the treatment of psoriasis.
Benoxaprofen induced toxicity in isolated rat hepatocytes
Toxicology 1986 Sep;40(3):327-39.PMID:3750332DOI:10.1016/0300-483x(86)90064-8.
The toxicity of Benoxaprofen, a non-steroidal anti-inflammatory compound was investigated using rat hepatic microsomal and isolated hepatocyte suspensions. In microsomes, Benoxaprofen produced a Type I binding spectra and competitively inhibited (ki 380 microM) the oxidative metabolism of aminopyrine. Marked toxicity was observed following incubation of Benoxaprofen with isolated hepatocytes from either untreated, phenobarbitone (PB) or 3-methylcholanthrene (3-MC) pretreated male rats. In untreated hepatocytes increases in the intracellular lactate/pyruvate (L/P) ratio and alanine aminotransferase (ALT) release were related to the Benoxaprofen concentration and duration of incubation. Alterations in L/P ratio preceded the release of cytosolic ALT and at 4 h a well defined dose-response relationship existed between the Benoxaprofen concentration and the observed increases in the L/P ratio and ALT release. Pretreatment of animals with either PB or 3-MC did not affect the temporal nature nor the magnitude of the hepatocyte response to Benoxaprofen. In addition, inhibitors of cytochrome P-450 isozymes (SKF-525A, metyrapone and alpha-napthoflavone) were ineffective with regard to modifying the observed toxicity. The results of this study suggest that hepatic cytochrome P-450 mediated metabolism may not be implicated in the toxicity of Benoxaprofen in isolated hepatocytes. However, alterations in the cellular redox state and evidence of plasma membrane bleb formation suggest that Benoxaprofen may uncouple oxidative phosphorylation and disturb intracellular calcium ion homeostasis.
Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent Benoxaprofen
Pharmacotherapy 1982 Nov-Dec;2(6):354-66.PMID:6762531DOI:10.1002/j.1875-9114.1982.tb03212.x.
Benoxaprofen is a nonsteroidal anti-inflammatory agent that belongs to the arylalkanoic acid class of antirheumatic drugs. Animal studies have demonstrated that it has analgesic, antipyretic, and anti-inflammatory properties. Although Benoxaprofen is a relatively weak inhibitor of cyclo-oxygenase in in vitro systems, inhibits lipoxygenase in other systems, and inhibits monocyte migration in some animal models of inflammation, it has not been established that it is unique with regard to these actions. Benoxaprofen undergoes hepatic metabolism via glucuronidation as the primary route of elimination and has a half-life of 28-35 hr. Clinical trials have demonstrated that its analgesic and anti-inflammatory properties are useful in the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Once daily dosing of 300-600 mg is effective for many patients. In addition to gastrointestinal intolerance, photosensitivity and onycholysis are the most frequent adverse effects encountered. Recent reports of fatal cholestatic jaundice often associated with nephrotoxicity led to the withdrawal of Benoxaprofen from world markets. It is uncertain whether it will once again be available for clinical use.